Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here’s a easy Read
https://www.leafly.com/news/science-tech/what-is-delta8-thc
Now you take the average TCH9 smokers
Me some 50+ Years THC9 — Not much High or euphoria
Someone as me starting out 50 years ago - Probably better as the tolerance hasn’t built up in me and back then was only about 5% THC and today in Legal States maybe 30% THC Products and that to me would be like someone starting out “Delta-8” and never having any tolerance to THC
Same EUPHORIA the High
Hope that helps explaining
Instagram “LazyDazeLaredo” and probably need Instagram app
Last posted from them 17 Hours Ago
https://www.instagram.com/p/CagTmg6MiRy/?utm_medium=copy_link
Should show what LazyDaze is pushing in recent upload
Click the Red Circle around LazyDaze Laredo
https://instagram.com/lazydazelaredo?utm_medium=copy_link
As for me - I like the info you give and nothing wrong with that to me
I’d even tell you to grab that last Mod Spot here and would be right infront of my handle here listed as Mod, they go by the birthdate of IHUB
Fair Play is always good for Shareholders
Let me ask you this
Your in Pinkyland for Odds of picking a good one - Strike it Rich kinda play
So if None of the Notes is collectible and already some in play as converted shares
Remaining Notes wiped out as it’s owed to Mark Kilchesky- aka “Miller” and brother Richard Kilchesky and what’s left in Richard NORTHWOODS is the interest of Illegal gotten shares won’t get got
Let’s switch to MM’s side of things, say Kilchesky clan held their shares as MM’s knew they had but trashed the stock knowing the clan already - MM’s know a lot and play themselves on stocks
Either-way it’s a Pickyland-Play
Wait for the TickerCloud or BreakOut Boards
JMO - You should have Shares
Anyway forget the Question as I’m fine with what I know as a Play here in PennyLand
And thanks for your effort on informing Shareholders what they have here as a Risk in Pennyland
Under Notes of same Filings or your Suppressed Image link
Page F-11 https://www.otcmarkets.com/otcapi/company/financial-report/295562/content
You act as if you finally read $MEDH Filings
All old news and most here know the story of what you Post
You really believe they are still selling shares now ?
SEC FBI and others I didn’t name Investigating the clan
To me it’s safer play than most OTC Stocks because of the Eyes watching them now
JMO
Don’t forget Northwoods Elite llc Richard Kilchesky $18,500 Note for .0001’s, 215,000,000 already Issued and still $5,653 left on the Note
You think their still Selling Shares with SEC and others watching Kilchesky‘s now
11/29/20 New Issuance 10,000,000 Common .0001 Northwoods Elite llc Richard Kilchesky
12/17/20 New Issuance 10,000,000 Common .0001 Northwoods Elite llc Richard Kilchesky
01/04/21 New Issuance 10,000,000 Common .0001 Northwoods Elite llc Richard Kilchesky
01/26/21 New Issuance 10,000,000 Common .0001 Northwoods Elite llc Richard Kilchesky
02/03/21 New Issuance 10,000,000 Common .0001 Northwoods Elite llc Richard Kilchesky
02/09/21 New Issuance 10,000,000 Common .0001 Northwoods Elite llc Richard Kilchesky
02/17/21 New Issuance 10,000,000 Common .0001 Northwoods Elite llc Richard Kilchesky
02/26/21 New Issuance 10,000,000 Common .0001 Northwoods Elite llc Richard Kilchesky
03/04/21 New Issuance 20,000,000 Common .0001 Northwoods Elite llc Richard Kilchesky
03/16/21 New Issuance 20,000,000 Common .0001 Northwoods Elite llc Richard Kilchesky
03/29/21 New Issuance 20,000,000 Common .0001 Northwoods Elite llc Richard Kilchesky
04/18/21 New Issuance 30,000,000 Common .0001 Northwoods Elite llc Richard Kilchesky
05/24/21 New Issuance 45,000,000 Common .0001 Northwoods Elite llc Richard Kilchesky
All Debt Conversion
https://www.otcmarkets.com/otcapi/company/financial-report/295562/content
And probably see more with the New Filings - A Happy Thought would be Hans helping the SEC but SEC needs no help with Filings leaving a trail back to where it started
Gamble here but what the Hell As the OTC is all about flipping Shares
Until a Company makes a spot to generate Cash and Rewards Shareholders
FAIMS Marijuana Breathalyzer Technology at the Texas Impaired Driving Forum
https://webfiles.thecse.com/Cannabix_Technologies_Presents_FAIMS_at_Texas_Forum_Feb_24_2021_final.pdf?rna03yHHQZI4wfe8FGINlk7x.hPSQCft
Today — Texas Statewide Impaired Driving Forum
Dr. Jared Boock of Cannabix Speaks between 11:00-12:00 CST (3 or 4 speakers at that time)
https://s6.goeshow.com/tti/txidf/2022/registration_form.cfm
Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Begins-Manufacturing-of-Repirinast-and-Launches-New-Chronic-Kidney-Disease-Research-Program?id=344878
What Are the Listing Requirements for the NASDAQ?
https://www.investopedia.com/ask/answers/nasdaq-listing-requirements/#toc-listing-requirements-for-all-companies
Easy Read but a Uphill battle for $AGNPF getting Listed — JMO
Selling Shares doesn’t work but the only one close is Shareholders having $55M Equity
A total the present time that’s $34.375 $AGNPF
Double the shares with sell of shares same as 1.6M Shareholders now
$17.1875 $AGNPF — I can see that after touching almost $10 $AGNPF and then give themselves $3.60 $AGNPF Options
Friends and Family Plan
As for King Cobra - What he took over $35M to spend with their Cash on Hand and $AGNPF saw some and even spent the Cash for the Force Warrants were pushed “Early Buy” or lose - I would expect will see more - JMO
Approximate date of commencement of proposed sale to the public:
https://www.otcmarkets.com/filing/html?id=15587003&guid=nSWwk67MdXhEY0h
It’s Coming - JMO
Lazydaze Pflugervil
1202 Farm to Market 685 Suite A5
78660 Pflugerville, United States
CANNABIS STORE
trustpit ratingtrustpit ratingtrustpit ratingtrustpit ratingtrustpit rating 4.5
Lazydaze +Coffeeshop
2166 Jackson Keller Rd
78213 San Antonio, United States
COFFEE SHOP
trustpit ratingtrustpit ratingtrustpit ratingtrustpit ratingtrustpit rating 4.5
Lazydaze +Coffeeshop
1738 W Anderson Ln
78757 Austin, United States
COFFEE SHOP
trustpit ratingtrustpit ratingtrustpit ratingtrustpit ratingtrustpit rating 4.5
Lazydaze Cafe
1738 b W Anderson Ln
78757 Austin, United States
trustpit ratingtrustpit ratingtrustpit ratingtrustpit ratingtrustpit rating 4.0
Lazydaze+ San Marcos
718 E Hopkins St
78666 San Marcos, United States
CAFE
trustpit ratingtrustpit ratingtrustpit ratingtrustpit ratingtrustpit rating 5.0
Lazydaze Countercul
4200 W Stan Schlueter Loop Ste 107
76549 Killeen, United States
COFFEE SHOP
trustpit ratingtrustpit ratingtrustpit ratingtrustpit ratingtrustpit rating 5.0
Lazydaze Countercul
435 W Liberty St
44256 Medina, United States
HOME GOODS STORE
trustpit ratingtrustpit ratingtrustpit ratingtrustpit ratingtrustpit rating 3.5
Lazydaze Countercul
531 San Pedro Ave
78212 San Antonio, United States
trustpit ratingtrustpit ratingtrustpit ratingtrustpit ratingtrustpit rating 4.5
Lazydaze Countercul
607 San Jacinto Blvd
78701 Austin, United States
trustpit ratingtrustpit ratingtrustpit ratingtrustpit ratingtrustpit rating 4.0
Lazydaze Countercul
5104 Butler St
15201 Pittsburgh, United States
CAFE
https://m.trustfeed.com/RestaurantDetails.aspx?requestid=mainsearch&keyword=Lazydaze&CountryName=United%20States&location=United%20States&countryCode=us
New Franchise opening in New Mexico. Recreational sales begin in April. Here we grow again!!
New Franchise opening in New Mexico. Recreational sales begin in April. Here we grow again!! $medh @VerdosaHoldings @DazedCorp #CannabisCommunity #SAFEBanking #MSOgang pic.twitter.com/rjRCVooe2L
— Lazydaze Official (@lazydazeco) February 17, 2022
It should but Shares Cancelled was to himself, (the CEO), Company forwarded $50,000 to the Texas processing thing to reinvent a barn to a Processing Building that the CEO took to his own because of Issues they Company couldn’t be part of that did the Deal, then $50,000 from the Company to reinvent it.
Maybe that’s what was Cancelled — Who knows but those with the Shares to sell or cancel
Quote from today’s News Release
Cancellation of Convertible Debt
https://www.otcmarkets.com/stock/CNNA/news/Cann-American-Corp-Announces-Cancellation-of-Convertible-Debt?id=344018
$AGNPF Vol 139 $AGN Vol 362
Sellers are taking a break
Here’s the CEO’s last Buy off the Market and is
$4.65 $AGNPF
Jan 12, 2022 (filed on Jan 17, 2022)
Insider Name:Moreau, Christopher Joseph
Ownership Type:Direct Ownership
Securities:Common Shares
Nature of Transaction:10 - Acquisition or disposition in the public market
# or value acquired/disposed of:640
Price:$5.89
https://m.canadianinsider.com/node/7?menu_tickersearch=AGN+%7C+Algernon+Pharmaceuticals
**. After they gave themselves $4.10 $AGN Options or $3.23 $AGNPF
Can the Psychedelic Drug DMT Take Algernon Pharmaceuticals to the Next Level?
Join Algernon Pharmaceuticals CEO Christopher J. Moreau and Streetwise Live! Host Cyndi Edwards as they discuss the potential of psychedelic drug DMT as a new stroke therapy.
Also, we hear from two medical experts, Dr. Anthony Rudd, Global Stroke Expert and Dr. Robert Simister, Director of the Stroke Centre in London England, as they discuss the need for a new stroke treatment in light of today's treatments being so very limited.
”No - never saw that coming until post or news of Nash reverse merger and leaning then going another direction as to what they did with NaNose - Should have seen it then but felt they got what needed from NaNose for 1M Shares count with the Reverse Split 1/2 making 500,000 and now only 5,000 after this last Reverse @ 1 for 100 held”
Value today would be $30,000 for 5,000 $AGNPF and shows $108 $AGN or $85.22 $AGNPF when NaNose probably received Shares
April 11, 2016 price above $108 and NaNose 1M Deal on April 16, 2016 probably but Filed in May I believe of 1M Shares
https://geoinvesting.com/breathtec-biomedical-bthcf-pumped-paragon/
Charts
https://www.thecse.com/en/listings/life-sciences/algernon-pharmaceuticals-inc
It’s a wash - $30,000 today $AGNPF vs $426,200 $AGNPF then for the same 5,000 shares today
Reverse math is $0.426 $BreathTec share price, 4/11/2016
Hindsight is still a NO as to what happen but I understand why now with Yost with Owlstone which is still like NaNose tech with a touch of Yost tech to getting to a real hand-held
I talked with Billy Boyle’s back when BreathTec started and I was DD - trying to learn the FAIMS
Billy was struggling for Cash after his father allowed him to take that part over from his Company and I talked about Investing and told him of Dr Yost was working with BreathTec to push FAIMS into a Hand-Held which the guy that put together BreathTec also pushing Cannabix Breathalyzer
He said he wanted no part in hurting folks by catching them having fun, he did understand about those that are Impaired and maybe save those from the Impaired Folks
Yost now with him Medical side, (Germany side of the World), and on the same tech of Yost FAIMS helped by BreathTec funding and now Owlstone tech, NaNose tech, combined together to get a standalone Hand-Held by using Yost FAIMS touch - linking FAIMS threw a portal like NaNose uses, but probably with Owlstone tech on a held-held already in production but sample back to a lab
Cannabix is (4) different tech’s, (my opinion only with no proof), with only the NaNose tech of linking to main stand-by FAIMS spectrometer (Probably 5G), with Owlstone tech on collection device that-is a caught sample, and FAIMS for the recent of uses folks, then the Hounds type tech side for detecting the need for all the rest, of the Big Guns FAIMS tech - Just a Guess - Who really knows till done
Count the shares and do they need Cash to further the Tech or Trials
COVID tester coming probably is my guess and it’s a shame $AGNPF / $BreathTec won’t see any of that
(Gave up the rights to Yost FAIMS, the elliptical electrode - But maybe being elliptical doesn’t matter anymore)
That last line I gave —Maybe a COVID hand held - Just what King Cobra is all about
Create something everyone wants to Invest-In and sell them shares
Why ?? So he can raise the Cash for Friends and Family - I mean Company’s Payroll and then a Product to sell
JMO
Pennyland all about Charts and when their collecting or selling shares to make Money , Drive it down and give themselves Options and run it up to sell off shares
Holding what ?? Under 5% but do have controls to sham the Shareholders. — Pennyland - JMO
I’m a Share Counter and know Pennyland is all about Selling Shares or the Dilution to make the Cash to do what they promise as a Company or say will happen, Generating Cash with No-Revenue makes Selling Shares the only game
Giving themselves Options below the 50Day Moving Average
https://stockcharts.com/c-sc/sc?s=agnpf&p=D&b=5&g=0&i=0&r=1642853837969
Sad in my Book
Now the CEO has been Buying $5 to $4.31. $AGN off the Open Market or $3.40 $AGNPF
https://m.canadianinsider.com/node/7?menu_tickersearch=AGN+%7C+Algernon+Pharmaceuticals
Here’s one I really don’t understand
Outstanding: 1,674,868 on February 7, 2022
Monthly 5th Report
https://webfiles.thecse.com/1_-_Algernon_-_CSE_Form_7_-_January.pdf?Ci_LViNgoxHck0lwkkIQbgn_9glsinN9
Outstanding: 114,144,104 for February 5, 2022
Monthly 5th Report
https://webfiles.thecse.com/Cannabix_Monthly_Progress_Report_Form_7_Feb_5_2022.pdf?t3OAGyhWQVkLncaCtRGWUImfa919rBAm
Look at it this way — They finally Completed It
1st for a longtime for King Cobra Group
What I hate is all the Cancelled Options from $20 to $39 so you could then give more now at $3.21 $AGNPF
Granted the CFO lost his after leaving Company
$3.21 $AGNPF is below any levels for the Stock Holders of $AGNPF
https://stockcharts.com/c-sc/sc?s=agnpf&p=D&b=5&g=0&i=0&r=1642853837969
Even available for Shorts when touch $9 $AGNPF
And to UPLIST you need about the Outstanding in the Public Hands to UPLIST Nasdaq
So I don’t expect those with the shares to not-sell as their needed for a (1) Requirement for Nasdaq
Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
VANCOUVER, British Columbia, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company, is pleased to announce that it has completed enrollment in its Phase 2 NP-120 (“Ifenprodil”) idiopathic pulmonary fibrosis (“IPF’) and chronic cough study. The Company is projecting a data readout in calendar Q2, 2022.
“We are very pleased to announce this update to the market on our IPF and chronic cough study and we look forward to having it completed and presenting the data,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
Phase 2 IPF & Chronic Cough Study Summary
The purpose of this proof-of-concept open label 20 patient Phase 2 human trial is to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients (including biomarkers of fibrosis) and its associated cough. There are 7 sites in total participating in the study with 5 located in Australia and 2 in New Zealand.
Ifenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a mouse model of IPF. In addition, Ifenprodil significantly both reduced cough frequency and delayed onset in a guinea pig acute cough model.
About Ifenprodil
Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils and certain types of cancer cells.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Outstanding Shares 690,499,016 posted 02/01/2022
https://www.otcmarkets.com/stock/MEDH/security
Are You Ready To Rumble !!
Finally! TA came through!! $medh
Finally! TA came through!! $medh
— the 1 & Only HANS (@The1OnlyHans) February 2, 2022
It’s coming - Just got to wait the game out
Cannabix Technologies Develops Version 4.0 of THC Breath Analyzer Device
https://cannabixtechnologies.com/investors/news-releases/cannabix-technologies-develops-version-4.0-of-thc-breath-analyzer-device/
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
https://webfiles.thecse.com/AGN2022AGMNtcMtg.pdf?xMmCMDZCXRuTApfo.oC0nLYXuyrgvhkL=
INFORMATION CIRCULAR
https://webfiles.thecse.com/AGN2022AGMIC.pdf?Qz1LpLs4t96K0gH4eexyFn2EYC8sdRzk=
Proxy
https://webfiles.thecse.com/AGN2022AGMproxy.pdf?WPD7l.zxPPzdR8pDaFylAP6n7zNeDvNg=
ALGERNON PHARMACEUTICALS ANNUAL INFORMATION FORM
https://webfiles.thecse.com/Algernon_Aug_31_2021_AIF.pdf?z49ccUifBBYjmZ5Pd5PlHlLQTDUVCCkw
Hans is tweeting again
Something like this pic.twitter.com/gFhITiAkfF
— the 1 & Only HANS (@The1OnlyHans) January 26, 2022
Looks to me $MEDH ready to climb some more
https://stockcharts.com/c-sc/sc?s=MEDH&p=D&b=5&g=0&i=0&r=1642853837969
CODE OF BUSINESS CONDUCT AND ETHICS
https://sedar-filings-backup.thecse.com/00037722/2201241528375632.pdf
Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property
Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property
VANCOUVER, British Columbia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to disclose that as part of its intellectual property patent applications filed in early 2021 for AP-188 (“N,N-dimethyltryptamine” or “DMT”), the Company included novel salt forms of DMT. A novel salt form of a drug is a new and separate structure from the original compound and is considered a new composition of matter.
Many drug compounds’ core structures can often be paired with a salt. Different salts can improve the core drug in several ways, including improved efficacy, safety/tolerability, and stability.
The Company believes that it has maximized its intellectual property position around DMT, which includes filing patent applications for new novel salt forms, as outlined herein, as well as dosing, formulation, and method of use patent applications for stroke rehabilitation.
The Company recently announced on January 18, 2022, that it has filed a combined Clinical Trials of Investigational Medicinal Products and Ethics Approval application, with the United Kingdom Medicines and Healthcare Products Regulatory Agency for its planned Phase 1 DMT clinical human stroke study.
About DMT
N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT occurs naturally in many plant species and animals and has been used in religious ceremonies as a traditional spiritual medicine by indigenous people in the Amazonian basin. DMT can also be synthesised in a laboratory.
Several preclinical studies have demonstrated that DMT helps mitigate tissue damage and promote neurogenesis as well as structural and functional neural plasticity, with significance. These are key factors involved in the brain’s ability to form and reorganize synaptic connections, which are needed for healing following a brain injury.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
$AGN closed today $9.71 so $7.76 $AGNPF Open tomorrow